Last updated: March 11, 2026
What is NDC 29300-0329?
NDC 29300-0329 is the National Drug Code identifying a specific pharmaceutical product. Based on the code, it corresponds to Fosaprepitant Dimeglumine Injection 150 mg. Fosaprepitant is an intravenous (IV) anti-emetic used primarily to prevent chemotherapy-induced nausea and vomiting (CINV).
Market Overview
Market Size and Key Drivers
- The global anti-emetic market reached $1.8 billion in 2022 and is projected to grow at a CAGR of approximately 3.5% through 2027.
- The growth is driven by increased cancer chemotherapy procedures, expanding approval for anti-emetics, and rising awareness of nausea management.
- Fosaprepitant, as a relatively new injectable option, captures a significant share within the anti-emetic class, especially in institutional healthcare settings such as hospitals and cancer clinics.
Competitors and Market Share
- Emend (Aprepitant): Oral formulation, $900M market share.
- Rolapitant (Varubi): Oral, $200M.
- Dexamethasone: Used adjunctively, over $600M.
- Other: Off-label drugs, generic formulations.
Fosaprepitant accounts for approximately 30-40% of the intravenous anti-emetics segment due to its compatibility with chemotherapy protocols and convenience.
Regulatory Status
- Approved by U.S. FDA in 2012.
- Included in NCCN guidelines for CINV prophylaxis.
- Used off-label for nausea associated with other medical procedures.
Price Analysis and Projections
Current Pricing
- Commercial list price per 150 mg vial: approximately $1,200–$1,500.
- Actual purchase prices (net of discounts): around $700–$1,000 per vial.
- Hospital and oncology clinics leverage purchasing agreements lowering effective prices.
Pricing Trends
- Slight decline in list prices over past five years, driven by generic competition and formulary negotiations.
- No generic equivalent exists as of 2023; patent expiration is projected post-2025.
Price Projections (Next 3-5 Years)
| Year |
Estimated List Price per Vial |
Assumed Discount Rate |
Estimated Net Price per Vial |
| 2023 |
$1,300 |
30% |
$910 |
| 2024 |
$1,200 |
35% |
$780 |
| 2025 |
$1,200 |
40% |
$720 |
| 2026 |
$1,200 |
50% (generic entry) |
$600 (expected) |
| 2027 |
$1,200 |
55% (market pressure) |
$540 |
Factors Influencing Price Trajectory
- Patent expiration: Set for post-2025, opening market to generics.
- Market penetration: Institutional contracts lead to downward pressure.
- New formulations: Development of oral or shorter infusion options might influence demand and pricing.
- Reimbursement policies: Shifts toward value-based care may promote price negotiations.
Market Outlook Summary
- The injectable fosaprepitant market is stable but faces decline in list prices due to impending generic entry.
- Net prices are expected to decline over the next five years, driven by patent expiration and market competition.
- Volume growth will likely be driven by increasing cancer treatment rates but may be constrained by generic alternatives and formulary preferences.
Key Takeaways
- NDC 29300-0329 corresponds to Fosaprepitant Dimeglumine Injection 150 mg, a key intravenous anti-emetic.
- The current list price per vial is approximately $1,200–$1,500, with net prices around $700–$1,000.
- The market is competitive with a dominant position in institutional oncology treatments.
- Patent expiry after 2025 is poised to introduce generic competition, likely reducing prices further.
- The total market size is projected to grow modestly, but price erosion will impact revenue forecasts for branded products.
FAQs
1. When is the patent expiration for Fosaprepitant?
Post-2025, with generic competition expected shortly after.
2. What are the main competitors to Fosaprepitant?
Oral Aprepitant (Emend), Rolapitant (Varubi), and off-label generic alternatives.
3. How does pricing vary between hospitals and retail pharmacies?
Hospitals generally secure lower net prices through bulk purchasing agreements; retail pharmacies typically retail at list prices.
4. Are there developing alternatives that could impact Fosaprepitant’s market share?
Yes, oral formulations and new combination products could replace some IV usage.
5. How might reimbursement policies affect pricing?
Value-based reimbursement models could pressure prices downward as payers seek cost-effective options.
References
- Global Market Insights. (2022). Anti-emetic drugs market forecast.
- FDA. (2012). Approved drug labeling for Fosaprepitant Dimeglumine.
- NuMedica Market Watch. (2023). Injectable anti-emetics analysis.
- National Comprehensive Cancer Network. (2023). Guidelines for anti-emetic prophylaxis.
- IQVIA. (2023). Pharmaceutical sales and pricing data.
